Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MK-0616 for Prevention of Major Adverse Cardiovascular Events
jRCT2071230064Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and atherosclerotic disease comparing MK-0616 20 mg QD with Placebo QD (2 arms). Primary endpoint: Time to first CHD death-based MACE plus event. Started Oct 2023; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on jRCT2071230064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230064.